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Available online 23 June 2016Objectives: Although drug eluting stents (DES) have documented convenience in bifurcation lesions, possible un-
favorable effects on small side branch ostium (SBO) remain a question.We aimed to explore the effects of DES on
small jailed SBs (1.5–2.25 mm) which originated from the lesion on the main vessel and were not treated with
either stenting or balloon dilatation.
Methods: Angiographic data of 107 consecutive patients (129 SB) with Medina 1,1,1 or 1,1,0 lesions were evalu-
ated at the time of procedure and at the follow-up.
Results: Of all DES used, 70 (54.7%) was sirolimus-eluting, 39 (30.5%) was paclitaxel-eluting and 20 (14.8%) was
zotarolimus-eluting. The diameter of SBs was 1.84 ± 0.41mmwith a stenosis of 20.7± 26.6% at SBO at baseline.
The lesion at the SBO had progressed after the procedurewhen the pre vs postprocedure values and follow-up vs
pre-procedure values are compared (20.7± 26.6% vs 29.4± 27.4%; p b 0.0001 and 25.4± 25.1 vs 20.7 ± 26.6%;
p = 0.004 respectively). A signiﬁcant reduction in stenosis was revealed over the follow-up (29.4 ± 27.4 vs
25.4 ± 25.1 respectively; p = 0.013). The severity of the disease at the SBO at baseline was the only parameter
that affected the severity of SB stenosis in acute, longterm and follow-up. Additional parameters with inﬂuence
on SB patency at different times were female gender, stent deployment with low pressure, cTFC of the main
lesion, age, cTFC of the lesion, late loss index and the preprocedure TIMI ﬂow grade of the SB.
Conclusions: Although there was a signiﬁcant deterioration of SBO immediately after stenting, follow-up data
showed that the lesion at SBO improved but remained worse than baseline.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Side branch1. Introduction
Coronary bifurcation sites which are under pronounced endothelial
shear stress, are particularly prone to atherosclerotic process [1]. Bifur-
cation lesions represent one ﬁfth of all coronary interventions with
higher complication and lower long term patency rates in which, both
long term restenosis and acute occlusion/narrowing pose major prob-
lems for the treatment [2]. Current approach is treating themain branch
(MB) with a stent and provisional stenting of the clinically signiﬁcant
side branch (SB) [2,3]. Consequently, some of the smaller side branches
are left untreated to their fate on operator's judgment or due to techni-
cal challenges.With baremetal stents, the SBs at the level ofmain lesion
were frequently sacriﬁced. After introduction of drug eluting stents
(DES), positive data have been accumulated on the stent behavior andFaculty of Medicine, Research
ag, Turkey.
eliability and freedom from bias
land Ltd. This is an open access articllow rates of restenosis, making DES as the stent of choice in most pa-
tients [2]. Yet, skepticism on the possible unfavorable effects of antipro-
liferative and anti-inﬂammatory properties of DES on endothelization of
small SB with the risk of early or late thrombosis remains as a question.
Herein this study, we aimed to explore the immediate and long term
(6months) effects of DES on small jailed SBs (1.5–2.25mm)which orig-
inate at the level of the lesion on the MB and do not receive any
intervention.
2. Methods
In the study, a ‘bifurcation lesion’ represented a coronary lesion
which resulted in narrowing of MB at the level where a SB originates,
while the side branch ostium (SBO) may or may not be diseased. This
deﬁnition included Medina 1,1,0 and 1,1,1 lesions. Only the small side
branches with a diameter of 1.5 mm to 2.25 mm originating at the
level of lesion and were not treated with dilatation or stenting are
analyzed.
After approval from local Ethics Committee, 107 consecutive pa-
tients with stable coronary artery disease and bifurcation lesions ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and angiographic characteristics of study population.
Number Percent
(%)
Mean ± SD
Demographic data
Female 20 18.7
Age, yrs 60.9 ± 10.0
Hypertension 101 78.3
Hyperchlosterolemia 91 70.5
Diabetes mellitus 48 37.2
Smoking 41 31.8
Family history 30 23.3
Angiographic data
Main vessel LAD 76 58.9
Cx 17 13.2
RCA 30 23.2
Obtus 3 2.3
Saphenous 1 0.8
LMCA 2 1.6
Reference diameter, mm 2.84 ± 0.39
Stent diameter, mm 2.89 ± 0.34
Lesion length, mm 13.53 ± 7.5
Lesion stenosis,% 73.39 ± 13.3
Stent length, mm 20.38 ± 7.4
Lesion type A 44 34.1
B1 40 31.0
B2 21 16.3
C 24 18.6
Predilatation 73 56.6
Maximum pressure, atm 13.8 ± 1.5
Diameter of side branch, mm 1.84 ± 0.41
Lesion at side branch ostium, % 20.7 ± 26.6
TIMI ﬂow of side branch 2.63 ± 0.7
Open stent design 25 19.4
Drug type SES 70 54.3
PES 39 30.2
ZES 20 15.6
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(PES) or Zotarolimus eluting stent (ZES)) was implanted were involved
to the study. All patients had control coronary angiography and they
gave informed consent before inclusion. The study protocol complied
with the Declaration of Helsinki.
Medical and angiographic records of 87male and 20 female patients
with a total of 129 SBs were evaluated. The traditional risk factors of the
patients recorded were gender, age, the presence of diabetes mellitus,
hypertension, family history of coronary artery disease, hyperlipidemia
and smoking. Age was categorized in three categories as b50, 50–65,
N65 years. The lesions were located on branching points of left anterior
descending artery (LAD), circumﬂex artery (Cx), right coronary artery
(RCA) and ‘protected’ left main coronary artery (LMCA).
3. Angiographic data
Both of the lesion on the MB and lesion on the SB, if any, were
evaluated quantitatively during coronary angiography. All quantitative
angiographic measurements were derived from QCA-Telemedicine
Technologies, MEDCON software. The measurements were made in di-
astole after calibration with the guiding catheter. The angiographic
data were analyzed before the procedure, immediately after the proce-
dure and at the follow-up coronary angiogram. At the time of follow-up
CAG, segment within 5 mm proximal and distal ends of the stent were
evaluated.
Among the angiographic parameters evaluated were lesion length,
reference diameter of MB, percent stenosis on the MB, lesion type clas-
siﬁed by ACC/AHA [4], TIMI ﬂow grade [5], corrected TIMI frame count
(cTFC) [6] of the MB and SB. Corrected TIMI frame count (cTCT),
which is an index of coronary perfusion, is considered as a predictor of
restenosis. It involves the frame count of contrast agent from the ostia
to the standardized segments of coronary arteries. For LAD, which is
longer when compared to other coronaries, this number is corrected
by dividing the calculated number by 1.7 [6]. In the study, cTFC is calcu-
lated for both main and side branches. The cTFC of the side branches
were calculated as the number of frames elapsed from the ostia to the
end of the evaluated side branch. Whether a predilatation of the MB
was employed or the maximal pressure achieved during stent deploy-
ment were also recorded. A pressure higher than 14 atmospheres was
designated as high pressure inﬂation. Late loss index (late loss/acute
gain) represents the percent loss of lumen diameter which was gained
immediately after the procedure and was also evaluated to reveal the
inﬂuence of restenosis on SBO. The SB involved was not treated with a
stent or balloon due to small vessel size or difﬁcult rewiring.
The difference between the severity of stenosis of SBO before and
immediately after the procedure reﬂects the acute effect of the
procedure and is designated as ‘acute effect’ in the text and tables. The
difference between the pre-procedure stenosis and stenosis of SB at
the follow-up angiogram, on the other hand, represents the long term
effect of the procedure and is entitled accordingly. Atherosclerosis is a
progressive disease and the course of the disease at the SBO during fol-
low-up is also evaluated by comparing the percent stenosis difference
between the immediately post-procedure and follow-up angiogram of
the side branches. For the purpose of the study this is designated as ‘dis-
ease course’.
4. Statistical analysis
Both mean ± standard deviation and median (minimum–maxi-
mum) values are used in the descriptive statistics of the data. The distri-
bution of the variables is tested by Kolmogorov–Simirnov test. The
quantitative data are analyzed by Mann–Whitney U test. Repetitive
measurements were analyzed by Wilcoxon test and Mc Nemar test.
The correlation of the variables is evaluated by Spearman correlation
analysis. All data is analyzed by SPSS 22.0 Software.5. Results
A total of 107 patients, 20(18.7%) female and 87(81.3%) male with a
mean age of 60.9 ± 10.1 years, are involved into the study. A follow-up
CAGwas carried outwithin 7.44±3.1months of index procedure. Of all
DES used, 70 (54.7%) was SES, 39 (30.5%) was PES and 20 (14.8%) was
ZES.
The demographic and angiographic characteristics of the study
population are presented in Table 1. Based on the demographic
characteristics, one third of the patients were diabetic with relatively
high risk criteria. Similarly, one third of the lesions possessed angio-
graphically high risk characteristics (ACC AHA classiﬁcation B2 and C).
In half of the patients, predilatation with 13.76 ± 1.5 atmosphere was
employed. The diameter of SBs was 1.84 ± 0.41 mmwith a stenosis of
20.7 ± 26.6% at the SBO.
When all the SBs are evaluated, 5 SBs (4%)were acutely lost after the
procedure, while the follow-up CAG revealed that 3 out of 5 acutely oc-
cluded SBs were recanalized. Only 1 SB was seen to be occluded on the
follow-up angiogram after good immediate result (0.008%).
A more detailed evaluation of outcome of MB stenting on SBO is
summarized in Tables 2, 3 and Fig. 1. The lesion at the SBO had
progressed severely after the procedure when the pre and post-
procedural values for lesion at SBO are compared (21 ± 27.3 vs
29.4 ± 27.4 respectively; p b 0.0001). Similarly, there was a signiﬁcant
increase in stenosis when the follow-up and pre-procedure values
were compared (25.4 ± 25.1 vs 21.5 ± 27.3 respectively; p = 0.004).
Interestingly, when we compared the post-procedure and follow-up
stenosis rates, a signiﬁcant reduction in stenosis was revealed over the
follow-up (29.4 ± 27.4 vs 25.4 ± 25.1 respectively; p = 0.013)
(Table 2). Table 3 shows the acute effect of the procedure on the distri-
bution of stenosis rates at SBO. There was a signiﬁcant increase in the
Table 2
Lesion at side branch ostium(%).
Pre-procedure Post-procedure P* Follow-up Pα P#
Mean ± SD 20.7 ± 26.6 29.4 ± 27.4 b0.0001 25.4 ± 25.1 0.004 0.013
Me (min–max) 10 (0–100) 23 (0–100) 19 (0–100)
Wilcoxon test.
P*— preprocedure vs postprocedure.
Pα — preprocedure vs follow-up.
P# — postprocedure vs follow-up.
p b 0.05 is considered statistically signiﬁcant and represented in bold.
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0.007).
The results of the study showed that the severity of the disease at the
SBO before the procedure is the only parameter that affected the sever-
ity of SB stenosis in acute, longterm and follow-up results. Additional
parameters with an inﬂuence on SB patency are as follows:
1. Female gender (p = 0.011), stent deployment with low pressure
(b14 atm) (p = 0.008) and cTFC of the main lesion (p = 0.043)
are shown to be the other determinants of the acute effects of MB
stenting.
2. Among the parameters affecting the patency of SB ostia on the long
term are; female gender (p = 0.001), age between 50 and 65 years
(p = 0.002), cTFC of the lesion (p = 0.005).
3. The factors affecting the disease course at SB ostium are shown to be
late loss index of the stent on the MB (p = 0.043) and the
preprocedure TIMI ﬂow grade of the SB (p = 0.000).
The parameters evaluated but not shown to have inﬂuence on the
patency of SBO at any time are the presence of cardiovascular risk fac-
tors (diabetesmellitus, hypertension, family history, smoking, hyperlip-
idemia), stent type (SES, PES or ZES), characteristics of the lesion onMB,
the diameter of SB and the cTFC of the SB.
6. Discussion
The treatment of bifurcation lesions continues to be a challengewith
no simple solution appropriate for every speciﬁc patient.When the SB is
small, it is usually compromised for the sake of MB, sometimes leading
to dramatic disappearance of the SB. Acute SB occlusion is the most
common cause of periprocedural myocardial infarction and is associat-
ed with increased mortality [7,8]. Recurrence of anginal symptoms
due to diseased SBO constitutes another problem. Therefore, the fate
of small side branches that did not receive any treatment during stent
implantation on main vessel is of considerable concern.
Herein this study, we wanted to explore the outcome of relatively
small jailed SBs (1.5–2.25 mm) that arise from the diseased segment
of the artery and received no treatment after DES implantation on the
MB. The bifurcation lesions involved were Medina 1,1,0 or 1,1,1 and
the DES used were SES, PES and ZES. We evaluated the disease at the
SBO quantitatively and recorded the % luminal stenosis at SBO together
with the acute total occlusion rates.
Our study revealed thatMB stenting has unfavorable immediate and
long term effects on small SBs assessed by % luminal stenosis at SBO. TheTable 3
Comparison of lesion at side branch ostium.
Pre-procedure Post-procedure
p⁎n % n %
Lesion at SB ostium b25% 84 65% 67 52% 0.007
25–50% 23 18% 33 26%
50–75 16 12% 19 15%
75b 6 5% 10 8%
Mc Nemar test.
p b 0.05 is considered statistically signiﬁcant and represented in bold.deterioration of SBO immediately after stenting was shown to decrease
on the follow-up but remained worse than the pre-intervention state.
In our study, the rate of acute occlusion of SB after DES implantation
in stable coronary artery disease was shown to be 4%. Fischman et al.
have documented in their study with BMS that acute SB occlusion oc-
curred in 6% of patientswhile other investigators have proposed various
results between 7 and 41% [9–12]. For SES, the rate of SB occlusion is
shown to be 10% [13]. For everolimus eluting stents, on the other
hand, the incidence of acute SB occlusion is reported as 4.1% [14]. This
ratio defers depending on the clinical scenario with the higher rates of
SB occlusion (22.5%) seen after stenting of the culprit lesion in acute
myocardial infarction [15].
The only predictor of SB occlusion in acute and chronic phase togeth-
er with the disease course is the % stenosis of the SB ostium before the
procedure [13]. This seems to be the result of plaque and carina shift to-
wards SBO [16,17]. Plaque shift or ‘snowplow phenomenon’ includes
the shift of the atherosclerotic plaque towards already diseased SB
[16]. Previous BMS studies have also shown that the predictors of
acute SB occlusion were stenotic SBO, the presence of SB originating
from the lesion, TIMI ﬂow lower than 3 on SB and balloon/ artery ratio
[18–21]. In the RAVEL study, the only predictor of acute SB occlusion
with SES implantation was shown to be the presence of severe lesion
on the SBO [13].
In our study, female gender was shown to have signiﬁcant effect on
both acute and long term results of DES implantation. This can be ex-
plained by the SB characteristics of female patients, since they tend to
have smaller (1.7mm in females vs 1.9mm inmales) andmore severely
diseased SBs (30% stenosis vs 18%). Another potential mechanism is
higher incidence of elastic recoil, vasospasm, and dissection in female.
These potentially reversible mechanisms of acute occlusion can also ex-
plain the 60% recanalization rate of acutely occluded SBs.
Interestingly, age between 50 and 65 years, which represented 51%
of the study population, was associated with worse outcome of SB
after DES implantation. Result was cross-checked by testing theFig. 1. Evolution of disease at side branch ostium.
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on SBO which revealed no correlation (p = 0.149). This is obviously
the result of the higher number of patients in this particular group and
also the progressive nature of the disease.
Another predictor of acute SB occlusion was identiﬁed as the lower
pressure stent (b14 atm) deployment. The study revealed that stent de-
ployment with a pressure lower than 14 atm is associated with worse
acute outcome on SB. This is in contradiction to the studies of BMS
that identiﬁed high pressure postdilatation (15.5 ± 3.3 atm) as a risk
factor for SB occlusion [22]. For DES, on the other hand, the optimum
pressure is the one that provides best stent apposition and strut opening
[23]. In our study, in which the mean reference diameter was 2.84 mm,
this optimum pressure seems to be more than 14 atm. Stent
malapposition may result in delayed endothelization and formation of
thrombi between the stent struts and SBO compromising the ﬂow.
The cTFC of the main lesion reﬂects the functional severity and
plaque burden of the lesion, and it is inevitable to see that lesions with
higher cTFC have higher incidence of acute and chronic deterioration
of the SB.
There has been no proven relationship between the open cell stent
design and SB occlusion. Cho et al. could not demonstrate any effect of
slotted tube, coil and hybrid stent design on acute or chronic SB occlu-
sion [24]. In our study, results show that, open cell designmayhave pos-
sible favorable effects on SB patency. The low incidence of SB occlusion
and predominance of stents with closed cell designmay have precluded
a statistically signiﬁcant difference.
Themain limitation of the study is the lack of clinical follow-up data.
Although postprocedure evaluation of cardiac biomarkers such as CK,
CK-MB or troponin could have demonstrated a periprocedural myocar-
dial infarction; inclusion of such data would not provide further infor-
mation on SB patency. The relatively small number of patients which
may limit the statistical power of the study is also a limitation.
7. Conclusion
With coronary stenting, most of the small SB originating at the level
of main lesion (Medina 1.1.0,1.1.1.) receive no intervention. In our
study, we sought to explore the acute and long term outcome of such
jailed SBs and found that; although there was a signiﬁcant deterioration
of SBO immediately after stenting, follow-up data showed that the le-
sion at SBO has decreased to some extent but remained worse than
the original state. The acute occlusion, however, occurred in only 4% of
SBwith a recanalization rate of 60%. The late total occlusion ratewas ex-
tremely low (0.008). The disease involvement of SBO was identiﬁed as
the main predictor of all times outcome, together with Female gender,
lower pressure stent deployment, cTFC of the main lesion and late loss
index of the stent as the contributors to acute or long term outcome.
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